Abstract
Enrofloxacin is a fluoroquinolone drug used to prevent and control bovine respiratory disease (BRD) complex in multiple or single doses, ranging from 7.5 to 12.5 mg/kg body weight. Here, we examined the effects of high and low doses of a single subcutaneously injected enrofloxacin on gut microbiota and resistome in calves. Thirty-five calves sourced for this study were divided into five groups: control (n = 7), two low dose groups (n = 14, 7.5 mg/kg), and two high dose groups (n = 14, 12.5 mg/kg). One group in the low and high dose groups was challenged with Mannheimia haemolytica to induce BRD. Both alpha and beta diversities were significantly different between pre- and post-treatment microbial communities (q < 0.05). The high dose caused a shift in a larger number of genera than the low dose. Using metagenomic ProxiMeta Hi-C, 32 unique antimicrobial resistance genes (ARGs) conferring resistance to six antibiotic classes were detected with their reservoirs, and the high dose favored clonal expansion of ARG-carrying bacterial hosts. In conclusion, enrofloxacin treatment can alter fecal microbiota and resistome irrespective of its dose. Hi-C sequencing provides significant benefits for unlocking new insights into the ARG ecology of complex samples; however, limitations in sample size and sequencing depth suggest that further work is required to validate the findings.
Highlights
Gut microbiota, consisting of bacteria, archaea, viruses, protozoa, and fungi, play vital roles in animals by conferring colonization resistance against pathogens, modulating immunity, and increasing food-conversion efficiency [1,2]
Calves in the sick groups, those infected with M. haemolytica before the enrofloxacin treatment, demonstrated mild signs of respiratory disease
The focus of this data analysis was on differences in dosing regimens and samples collected before and after enrofloxacin injection
Summary
Gut microbiota, consisting of bacteria, archaea, viruses, protozoa, and fungi, play vital roles in animals by conferring colonization resistance against pathogens, modulating immunity, and increasing food-conversion efficiency [1,2]. These beneficial commensal organisms are vulnerable to external aggressions, such as antibiotic exposure [3,4,5]. Despite their side effects, antibiotics have significantly improved animal health, welfare, and productivity since their discovery in the mid-20th century [6]. The global consumption of antimicrobials in food animals is expected to increase by 67% of the 2010 consumption level by 2030 [8], prompting a call for strict regulations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.